Tag: OTCB:BTHCF

May 15, 2020

Algernon Submits for Ethics Approval in Australia for Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, is pleased to announce that it has submitted for ethics approval in...
May 6, 2020

Algernon Receives First Ethics Approval for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia

Algernon Pharmaceuticals has received ethics approval for the planned Phase 2 clinical study of its re-purposed drug NP-120 (Ifenprodil).
May 5, 2020

Algernon Amends Terms of Private Placement Offering of Special Warrants

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) has amended certain terms of its brokered private placement, being conducted...
May 1, 2020

Algernon Pharmaceuticals Announces up to $5.0 Million Private Placement Offering of Special Warrants

Algernon Pharmaceuticals a clinical stage pharmaceutical development company, has entered into an agreement with Mackie Research Capital Corporation
April 30, 2020

Algernon Receives Clearance from Health Canada for Ifenprodil COVID-19 Phase 2b/3 Multinational Clinical Trial

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) has received a No Objection Letter from Health Canada to proceed...
April 29, 2020

Algernon Presents “The Science of Ifenprodil” on a Special BioPub Webcast Hosted by Dr. KSS, MD, PhD

Algernon is pleased to announce that Dr. Mark Williams will be making a presentation entitled “The Science of Ifenprodil” on...
April 23, 2020

Algernon Receives Regulatory and Ethics Approval for Phase 2 Ifenprodil COVID-19 Human Study in South Korea

Algernon, a clinical stage pharmaceutical development company, is pleased to announce that it has received approval from the Ministry of...